The two companies extend their existing partnership in rare genetic disease space.
The Danish clinical stage biopharmaceutical company Santaris Pharma focuses on the discovery and development of RNA-targeted therapies. Under the terms of agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development and Santaris will receive an upfront payment and will be eligible for research support, pre-clinical, clinical and sales milestones and royalties on each product emerging from the collaboration.
“Our collaboration with Shire is very important to us so we are very pleased with the decision to extend the agreement and allow for more drug discovery and development programs. We believe the LNA drug platform offers a unique opportunity to develop drugs against the rapidly expanding number of disease targets in the rare genetic disorder space,” stated Henrik Stage, President & CEO at Santaris Pharma A/S in the company press release.